Exposure to Antibiotics and Incidence of Bacteraemia Caused by Resistant Bacteria

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Aug 21, 2019

Keywords

ClinConnect Summary

This clinical trial is investigating the risk factors for a serious infection called bacteremia, which occurs when bacteria enter the bloodstream. The main goal is to understand how exposure to antibiotics might influence the likelihood of developing bacteremia caused by antibiotic-resistant bacteria in the community. The study will look at different types of bacteremia cases, including those that originate in the community and those that occur after a hospital stay. Additionally, researchers will explore how changes in antibiotic use in the general population might relate to the occurrence of these infections.

To participate in the trial, individuals must be hospitalized patients from specific hospitals in Paris (APHP) who had at least one positive blood culture indicating bacteremia between January 2010 and December 2018. Patients who had no infections during that time may also be included as a control group. Unfortunately, anyone under 18 years old cannot join the study. Participants can expect to be monitored for a year after their diagnosis to assess outcomes such as recovery, re-hospitalization, and the types of bacteria involved. This research aims to improve our understanding of how antibiotic use affects infection rates and could help in developing better treatment strategies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• For bacteraemia cohort:
• • All inpatient patients in a hospital of APHP between January 2010 and december 2018 with at least one haemoculture positive.
• • presence of at least a bacteremia as primary diagnosis, related diagnosis and associated diagnosis: A40 (streptococcus), A41 (staphylococcus, BGN, anaerobes, others), A32.7 (Listeria), A39.4 (meningocoele), A42.7 (Actinomyces), A02.1 (Salmonella), A54.8 (gonocoque), A48.0 (Clostridium).
• • and/or in biological data presence of at least a haemoculture positive to Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Acinetobacter Baumannii, Enterococcus faecium, Enterococcus faecalis, Enterobacter cloacae, Pseudomonas aeruginosa, Streptococcus sp., Salmonella sp., Clostridium difficile.
• For control cohort:
• • Patients cared in a hospital of APHP between 2010 and 2018 without infection. - Patients without infection of CIM-10 bacteraemia as primary diagnosis, related diagnosis and associated diagnosis, without haemoculture positive in microbiology.
• Exclusion Criteria:
• • - Patients aged \< 18 years